[1] Effect of aspirin and NSAIDs on risk and survival from colorectal cancer
Din FV, Theodoratou E, Farrington SM et al.
Aspirin is currently recommended to reduce the incidence of cardiovascular events in patients with risk factors for cardiovascular disease. However, it is well-known that the risks of aspirin (e.g. gastrointestinal bleeding) may outweigh its benefits. A recent review of randomized clinical trials showed that a daily aspirin reduces the mortality rates of several common cancers, including colorectal cancer (CRC), but there is not yet agreement on its recommended daily dosage or treatment duration in these settings (Lancet 2011;377:31–41).